Maturation inhibitor shows anti-HIV activity in single dose pilot study
18 April 2005. Related: Conference reports, Antiretrovirals.
Antiretrovirals
New antiretrovirals at 12th CROI
18 April 2005. Related: Conference reports, Antiretrovirals.
500mg saquinavir (Invirase) approved in Europe
18 April 2005. Related: Antiretrovirals.
Roche discontinue ddC and Fortovase
18 April 2005. Related: Antiretrovirals.
Needle-free injections for T-20 in US
18 April 2005. Related: Antiretrovirals.
Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen
29 March 2005. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM
29 March 2005. Related: Conference reports, Antiretrovirals.
Effective switching to atazanavir/ritonavir in clinical practice
29 March 2005. Related: Conference reports, Antiretrovirals.
Ritonavir boosting may not overcome interaction between atazanavir and nevirapine
29 March 2005. Related: Conference reports, Antiretrovirals.
TDM in Ugandan study highlights importance of refridgerated ritonavir
29 March 2005. Related: Conference reports, Antiretrovirals.
Lower d4T dose maintains virologic suppression and CD4 increases
29 March 2005. Related: Conference reports, Antiretrovirals.
Widespread adoption of post exposure prophylaxis (PEP) recommended in US
29 March 2005. Related: Antiretrovirals.
European Approval For Kivexa (abacavir/3TC)
29 March 2005. Related: Antiretrovirals.
500 mg saquinavir (Invirase) approved in US
29 March 2005. Related: Antiretrovirals.
Indinavir not recommended in pregnancy due to reduced pharmacokinetic levels
29 March 2005. Related: Antiretrovirals, Pregnancy.
25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’
31 January 2005. Related: Conference reports, Antiretrovirals.
Indinavir impairs endothelial function without insulin resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Tipranavir in treatment experienced patients: results from RESIST-1
31 January 2005. Related: Conference reports, Antiretrovirals.
Reverset: first data in patients with nucleoside resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Poor response with tenofovir and ddI backbone causes early study termination
31 January 2005. Related: Conference reports, Antiretrovirals.
Paradoxical CD4 response with tenofovir and ddI backbone
29 January 2005. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy
29 January 2005. Related: Conference reports, Antiretrovirals.
Limited stability of lopinavir/r (Kaletra) above 25°C
29 January 2005. Related: Conference reports, Antiretrovirals.
Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
29 January 2005. Related: Conference reports, Antiretrovirals.
Further genetic link to efavirenz absorption
29 January 2005. Related: Conference reports, Antiretrovirals.
Roche discontinue plans for nelfinavir 625mg formulation
29 January 2005. Related: Antiretrovirals.
The X4 files: sampling the science on HIV co-receptors in Bangkok
6 November 2004. Related: Conference reports, Antiretrovirals.
Six generics compare well with US-made ARVs
6 November 2004. Related: Antiretrovirals.
Viral load response at 4 weeks predicts treatment success
6 November 2004. Related: Antiretrovirals.
Resistance mutations in patients with persistent viraemia show need to improve clinical assays
6 November 2004. Related: Antiretrovirals.
Researchers call for new approach to assessing pipeline drugs for salvage patients
6 November 2004. Related: Antiretrovirals.
Another chance for 3TC in patients with M184V mutation?
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Kaletra monotherapy: small studies and early data
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies.
Lowering dose of d4T can maintain efficacy and reduce side effects
6 September 2004. Related: Conference reports, Antiretrovirals.
US FDA approves Glaxo and Gilead drug combinations
6 September 2004. Related: Antiretrovirals.
Abbott applies for once-daily license for lopinavir/r
6 September 2004. Related: Antiretrovirals.
AIDS activists respond to NIH decision on overriding HIV drug patent
6 September 2004. Related: Antiretrovirals.
Experimental compounds to target viral expression in latent cells
29 July 2004. Related: Conference reports, Antiretrovirals, Drug resistance.
CD4 entry criteria dropped for UK tipranavir named patient access
29 July 2004. Related: Antiretrovirals.
Tenofovir/FTC co-formulation expected in US by September
29 July 2004. Related: Antiretrovirals.
Guidelines for T-20
29 July 2004. Related: Antiretrovirals.
Persistent HIV viraemia fosters immunologic harm and viral evolution
29 July 2004. Related: Antiretrovirals.
Latent drug-resistant HIV harboured for years
29 July 2004. Related: Antiretrovirals.
Antiviral activity of foscarnet in salvage therapy
2 June 2004. Related: Antiretrovirals.
US treatment guidelines updated – March 2004
2 May 2004. Related: Antiretrovirals.
Atazanavir launched in UK
2 May 2004. Related: Antiretrovirals.
Tenofovir/FTC co-formulation application made to EMEA
2 May 2004. Related: Antiretrovirals.
Abacavir/3TC co-formulation available in expanded access
2 May 2004. Related: Antiretrovirals.
Treatment with generics: tolerability, safety and resistance
5 April 2004. Related: Antiretrovirals, Treatment access.
Drug levels can persist for more than two weeks after stopping efavirenz
3 April 2004. Related: Conference reports, Antiretrovirals, PK and drug interactions.
COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation
3 April 2004. Related: Conference reports, Antiretrovirals.
Studies of new pipeline drugs
3 April 2004. Related: Conference reports, Antiretrovirals.
Little benefit seen for treatment during acute infection
3 April 2004. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Gilead discontinues DAPD development
2 April 2004. Related: Antiretrovirals.
Abbott raises price of ritonavir in the US by over 400%
3 February 2004. Related: Antiretrovirals.
Development of T-1249 put on hold
3 February 2004. Related: Antiretrovirals.
Tenofovir/abacavir/3TC triple-nuke fails as maintenance regimen
3 February 2004. Related: Antiretrovirals.
New data on viral load ‘blips’ and the link to replication
3 February 2004. Related: Antiretrovirals.
Invirase and Fortovase: new dosing regimens approved by FDA
3 February 2004. Related: Antiretrovirals.
UK named-patient access to tipranavir
3 February 2004. Related: Antiretrovirals.
FDA labelling changes for indinavir (Crixivan)
3 February 2004. Related: Antiretrovirals.
Switching from efavirenz to nevirapine to avoid CNS side effects
1 December 2003. Related: Conference reports, Antiretrovirals, Side effects.
T20 is cost effective for UK purchasers
1 December 2003. Related: Conference reports, Antiretrovirals.
African patients and adherence in the UK
1 December 2003. Related: Conference reports, Antiretrovirals.
Five-year results of Kaletra-based therapy in treatment-naïve HIV patients
1 December 2003. Related: Conference reports, Antiretrovirals.